ArticleCancer research and treatment2010

Coexisting with clonal evolution and BCR-ABL mutant in CML patients treated with second-generation tyrosine kinase inhibitors predict the discrepancy of in vitro drug sensitivity.

Jae-Sook Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.